Advertisement
Sports

Report: Lance Armstrong weighing doping confession

Report: Lance Armstrong weighing doping confession
Lance Armstrong reportedly is weighing confessing to using performance-enhancing drugs.
(Thao Nguyen / Associated Press)

Lance Armstrong reportedly is weighing confessing to using banned performance-enhancing drugs and blood transfusions during his run of seven Tour de France titles.

Armstrong, who was stripped in October of his Tour titles and banned for life from competition by the U.S. Anti-Doping Agency, is pursuing the admission as a route to regain his eligibility to compete, the New York Times first reported Friday.

Advertisement

Armstrong’s attorney, Tim Herman, told the newspaper, “I suppose anything is possible. Right now, that’s not really on the table.”

Citing pressure from the cancer-fighting charity he helped create, Livestrong, Armstrong, 41, reportedly has held discussions with his longtime nemesis, USADA Chief Executive Travis Tygart, in an attempt to negotiate a lifting of the ban, one person told the New York Times.

Advertisement

Armstrong has competed in triathlons and running events since his lifetime ban took effect.

Efforts to reach Tygart and Armstrong’s representatives Friday night were not immediately successful.

Advertisement

The World Anti-Doping Code allows for lightened punishment for those who fully detail their doping protocol in a confession.

Armstrong lost a slew of endorsement deals after he was banned, and any confession would probably leave him in jeopardy of perjury accusations since he has given sworn statements denying he used banned substances in prior legal cases.

Advertisement

ALSO:

Kansas City Chiefs, Andy Reid in negotiations

Advertisement

Ray Lewis, once shunned by Disney, reportedly near ESPN deal

Rex Ryan tattoo: woman wearing Sanchez jersey, possibly ‘Tebowing’


Newsletter
Go beyond the scoreboard

Get the latest on L.A.'s teams in the daily Sports Report newsletter.

You may occasionally receive promotional content from the Los Angeles Times.
Advertisement